Insider sales reported by Ourania Tatsis at VRTX

Ourania Tatsis reported multiple secondary sales of common stock in filings relating to VRTX.

Rhea-AI Filing Summary

Ourania Tatsis reported multiple secondary sales of common stock in filings relating to VRTX. The reported transactions list sales of 4,500 shares on 12/03/2025, 4,500 shares on 01/07/2026, 466 shares on 02/11/2026, 1,500 shares on 02/13/2026, and 609 shares on 02/17/2026. The excerpt also shows 368 shares associated with restricted stock vesting from the issuer on 02/17/2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did VRTX disclose for Ourania Tatsis?

The filing shows reported sales of common stock: 4,500 shares on 12/03/2025 and 4,500 shares on 01/07/2026, plus additional smaller sales in February 2026. These entries are recorded as secondary sales by the reporting person.

Does the filing show any issuer-related share activity for VRTX?

Yes. The excerpt lists 368 shares tied to restricted stock vesting from the issuer on 02/17/2026, identified under compensation-related vesting rather than an open-market sale.

Are the sale dates and share counts for VRTX consolidated into a total?

The filing lists individual sales by date and share count—4,500; 4,500; 466; 1,500; 609—but does not present an aggregate total in the provided excerpt. Each transaction is shown with its specific date and amount.

Which broker or broker-dealer appears in the VRTX excerpt?

The excerpt names Fidelity Brokerage Services LLC and shows an entry with 368 shares and a dollar value, indicating broker involvement in the recorded transaction row associated with the Nasdaq-listed common shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/18/2026 - 12:28 PM EST Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001789815
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	VERTEX PHARMACEUTICALS INC / MA
SEC File Number	000-19319
Address of Issuer	50 NORTHERN AVENUE BOSTON MASSACHUSETTS 02210
Phone	6173416393
Name of Person for Whose Account the Securities are To Be Sold	Tatsis Ourania
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	368	174314.24	254034190	02/18/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/17/2026	Restricted Stock Vesting	Issuer			368	02/17/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Ourania Tatsis 50 Northern Avenue Boston MA 02210	Common	12/03/2025	4500	2024955.40
Ourania Tatsis 50 Northern Avenue Boston MA 02210	Common	01/07/2026	4500	2137455.00
Ourania Tatsis 50 Northern Avenue Boston MA 02210	Common	02/11/2026	466	214560.38
Ourania Tatsis 50 Northern Avenue Boston MA 02210	Common	02/13/2026	1500	749992.02
Ourania Tatsis 50 Northern Avenue Boston MA 02210	Common	02/17/2026	609	298081.14

144: Remarks and Signature

Remarks
Date of Notice	02/18/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	08/21/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Daniel Tucci, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Ourania Tatsis
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)